Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Where can you publish?
Find journals in COLORADO Profiles by department and year.

Contact Us
If you have any questions or feedback please contact us.

Christopher C Porter

TitleAssoc Professor Adjoint
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-PEDS
Phone303/724-4665

     Biography 
     awards and honors
    1995Peacock Family Award for Outstanding Performance in Gross Anatomy, Medical College of Georgia
    1998Alpha Omega Alpha Honor Medical Society, Medical College of Georgia
    2003 - 2004Ruth L. Kirschstein National Research Service Award, University of Colorado School of Medicine
    2004W.M. Thorkildson Research Fellowship, University of Colorado School of Medicine
    2005 - 2006Brent Eley/Brian Hicks Research Award, Brent Eley Foundation
    2008 - 2009Paul Calabresi Clinical Scholars Award, University of Colorado Cancer Center
    2011Scholars Award, Hyundai Hope on Wheels Foundation
    2013Acute Lymphoblastic Leukemia Young Investigator Award, CureSearch

     Overview 
     overview
    Dr. Porter is a Pediatric Hematologist-Oncologist with extensive training in basic, translational, and clinical sciences. After clinical training in pediatrics and pediatric hematology-oncology, he joined the laboratory of James DeGregori, Ph.D. for training in Biochemistry & Molecular Genetics. After fellowship, he was awarded the Paul Calabresi Clinical/Translational Scholars Award, which provided mentorship and training in Experimental Therapeutics with Lia Gore, M.D. He now runs a lab with the goal of improving the care of patients with leukemia. His lab now consists of 6 others focused on identifying and validating novel strategies for treating leukemia through functional genomic screening with RNA-interference libraries and translational murine models of disease. The clinical implications of these projects are emphasized, with the concrete goal of translating laboratory findings into clinical trials. In addition to directing the lab, he is the Study Chair/PI of an investigator initiated, NCI supported trial (NCT01456988) which translates preclinical data from similar functional genomics studies by "re-purposing" cyclosporine to inhibit WNT/calcineurin/NFAT signaling to sensitize BCR-ABL1+ leukemia cells to tyrosine kinase inhibition.

    Several members of the lab are currently working on further validation of one particular molecule, WEE1 that, when inhibited, sensitizes acute myeloid leukemia cells to cytarbaine. WEE1 is a cell cycle checkpoint protein kinase that is activated to stall cell cycle progression in the context of DNA damage. Using shRNA and a small molecule inhibitor in clinical development, the lab has demonstrated that inhbition of WEE1 is synergistic with cytarabine in inhibiting AML cell proliferation by inhibiting the S-phase checkpoint and inducing apoptosis. These data are being confirmed in mouse models of leukemia including primary patient xenografts. Clinical trials testing the combination of cytarabine and WEE1 inhibition are being planned.


     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Dimberg LY, Towers CG, Behbakht K, Hotz TJ, Kim J, Fosmire S, Porter CC, Tan AC, Thorburn A, Ford HL. A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. Mol Cancer Res. 2017 Jan 20.
      View in: PubMed
    2. Porter CC. Germ line mutations associated with leukemias. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):302-308.
      View in: PubMed
    3. Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR. Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers. Oncotarget. 2016 Mar 29; 7(13):15757-71.
      View in: PubMed
    4. Ford JB, Baturin D, Burleson TM, Van Linden AA, Kim YM, Porter CC. AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair. Oncotarget. 2015 Sep 29; 6(29):28001-10.
      View in: PubMed
    5. Jones CL, Gearheart CM, Fosmire S, Delgado-Martin C, Evensen NA, Bride K, Waanders AJ, Pais F, Wang J, Bhatla T, Bitterman DS, de Rijk SR, Bourgeois W, Dandekar S, Park E, Burleson TM, Madhusoodhan PP, Teachey DT, Raetz EA, Hermiston ML, Müschen M, Loh ML, Hunger SP, Zhang J, Garabedian MJ, Porter CC, Carroll WL. MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia. Blood. 2015 Nov 05; 126(19):2202-12.
      View in: PubMed
    6. Ellison MA, Thurman G, Gearheart CM, Seewald RH, Porter CC, Ambruso DR. INF-? Enhances Nox2 Activity by Upregulating phox Proteins When Applied to Differentiating PLB-985 Cells but Does Not Induce Nox2 Activity by Itself. PLoS One. 2015; 10(8):e0136766.
      View in: PubMed
    7. Kirkpatrick G, Noetzli L, Di Paola J, Porter CC. ETV6 mutations define a new cancer predisposition syndrome. Oncotarget. 2015 Jul 10; 6(19):16830-1.
      View in: PubMed
    8. Noetzli L, Lo RW, Lee-Sherick AB, Callaghan M, Noris P, Savoia A, Rajpurkar M, Jones K, Gowan K, Balduini CL, Pecci A, Gnan C, De Rocco D, Doubek M, Li L, Lu L, Leung R, Landolt-Marticorena C, Hunger S, Heller P, Gutierrez-Hartmann A, Xiayuan L, Pluthero FG, Rowley JW, Weyrich AS, Kahr WH, Porter CC, Di Paola J. Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia. Nat Genet. 2015 May; 47(5):535-8.
      View in: PubMed
    9. Gardner LA, Klawitter J, Gregory MA, Zaberezhnyy V, Baturin D, Pollyea DA, Takebe N, Christians U, Gore L, DeGregori J, Porter CC. Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia. Am J Hematol. 2014 Sep; 89(9):896-903.
      View in: PubMed
    10. Maycotte P, Gearheart CM, Barnard R, Aryal S, Mulcahy Levy JM, Fosmire SP, Hansen RJ, Morgan MJ, Porter CC, Gustafson DL, Thorburn A. STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. Cancer Res. 2014 May 01; 74(9):2579-90.
      View in: PubMed
    11. Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013 Dec; 12(12):2675-84.
      View in: PubMed
    12. Choudhary R, Baturin D, Fosmire S, Freed B, Porter CC. Knockdown of HPRT for selection of genetically modified human hematopoietic progenitor cells. PLoS One. 2013; 8(3):e59594.
      View in: PubMed
    13. Gore L, DeGregori J, Porter CC. Targeting developmental pathways in children with cancer: what price success? Lancet Oncol. 2013 Feb; 14(2):e70-8.
      View in: PubMed
    14. Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 2012 Aug 15; 72(16):4154-64.
      View in: PubMed
    15. Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nat Chem Biol. 2012 Jul; 8(7):646-54.
      View in: PubMed
    16. Porter CC, Kim J, Fosmire S, Gearheart CM, van Linden A, Baturin D, Zaberezhnyy V, Patel PR, Gao D, Tan AC, DeGregori J. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia. 2012 Jun; 26(6):1266-76.
      View in: PubMed
    17. Porter CC, Baturin D, Choudhary R, DeGregori J. Relative fitness of hematopoietic progenitors influences leukemia progression. Leukemia. 2011 May; 25(5):891-5.
      View in: PubMed
    18. Marusyk A, Porter CC, Zaberezhnyy V, DeGregori J. Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol. 2010 Mar 02; 8(3):e1000324.
      View in: PubMed
    19. Schlegel J, Redzic JS, Porter CC, Yurchenko V, Bukrinsky M, Labeikovsky W, Armstrong GS, Zhang F, Isern NG, DeGregori J, Hodges R, Eisenmesser EZ. Solution characterization of the extracellular region of CD147 and its interaction with its enzyme ligand cyclophilin A. J Mol Biol. 2009 Aug 21; 391(3):518-35.
      View in: PubMed
    20. Porter CC, Carver AE, Albano EA. Vincristine induced peripheral neuropathy potentiated by voriconazole in a patient with previously undiagnosed CMT1X. Pediatr Blood Cancer. 2009 Feb; 52(2):298-300.
      View in: PubMed
    21. Porter CC, Liang X, Gralla J, McGavran L, Albano EA. BCL6 expression correlates with monomorphic histology in children with posttransplantation lymphoproliferative disease. J Pediatr Hematol Oncol. 2008 Sep; 30(9):684-8.
      View in: PubMed
    22. Porter CC, DeGregori J. Interfering RNA-mediated purine analog resistance for in vitro and in vivo cell selection. Blood. 2008 Dec 01; 112(12):4466-74.
      View in: PubMed
    23. Gheorghe G, Albano EA, Porter CC, McGavran L, Wei Q, Meltesen L, Danielson SM, Liang X. Posttransplant Hodgkin lymphoma preceded by polymorphic posttransplant lymphoproliferative disorder: report of a pediatric case and review of the literature. J Pediatr Hematol Oncol. 2007 Feb; 29(2):112-6.
      View in: PubMed
    24. Bilousova G, Marusyk A, Porter CC, Cardiff RD, DeGregori J. Impaired DNA replication within progenitor cell pools promotes leukemogenesis. PLoS Biol. 2005 Dec; 3(12):e401.
      View in: PubMed
    25. Porter CC, Edwards KM, Zhu Y, Frangoul H. Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2004 Jan; 42(1):36-40.
      View in: PubMed
    26. Porter CC, Poehling KA, Hamilton R, Frangoul H, Cooper WO. Influenza immunization practices among pediatric oncologists. J Pediatr Hematol Oncol. 2003 Feb; 25(2):134-8.
      View in: PubMed
    Porter's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
    Physical Neighbors
    _

    Copyright © 2012 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.5.1)